Abbott Laboratories (ABT)
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
Abbott (ABT) closed the most recent trading day at $88.18, moving 1.64% from the previous trading session.
Abbott Laboratories Remains Structurally Undervalued
Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action. ABT trades at a 17.1% P/E and 35.1% sales multiple discount to peers, with DCF fair value estimates implying 21.8–39.4% upside. Growth is underpinned by the Exact Sciences acquisition, diagnostics megatrends, and global expansion in CGM, with FY26 guidance raised for both sales and EPS.
Abbott (ABT) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Abbott (ABT) closed at $89.17, indicating a -2.28% shift from the previous trading day.
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story
ABT's Exact Sciences acquisition expands its cancer diagnostics portfolio as new data and screening guidelines strengthen growth prospects.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Baron Discovery Fund Q1 2026: Who Moved The Needle
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential
Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target. ABT, trading at a forward P/E of 15.31x, is undervalued with robust liquidity, ongoing buybacks, and insider buying, despite segment weakness and lowered guidance.
